In Wasilla, Alaska, two people overdosed on what they believed was fentanyl in November 2024. One of them died. When federal lab results came back, the substance was not fentanyl at all. It was carfentanil, a synthetic opioid roughly 100 times more potent based on estimates derived from animal models, according to the Drug Enforcement Administration. The man who sold it was indicted on federal distribution charges.
That case was not an anomaly. According to reporting by the Associated Press, carfentanil is resurfacing across the United States after a years-long lull, blended into illegally manufactured fentanyl or pressed into counterfeit pills. Federal data now shows the drug appearing in overdose deaths, law enforcement seizures, and toxicology reports at levels that public health officials warn could reverse recent declines in overdose mortality.
Federal data confirms a pattern
The most detailed evidence comes from the CDC’s State Unintentional Drug Overdose Reporting System, or SUDORS. A CDC epidemiology report published in MMWR Volume 73 documented carfentanil’s reemergence in overdose deaths across participating U.S. jurisdictions, with maps and trend data showing the drug spreading geographically. In nearly every case, carfentanil appeared alongside illegally manufactured fentanyl, meaning the people who died almost certainly did not know what they had taken.
DEA laboratory data reinforces that picture at an industrial scale. The agency reported that its labs tested more than 100 kilograms of carfentanil mixed with fentanyl, fentanyl-related substances, or other drugs during calendar year 2024. The agency did not specify whether that figure was cumulative across all national laboratories or drawn from specific facilities. Regardless, the volume points to deliberate, large-scale blending operations rather than trace contamination in scattered samples.
The DEA’s 2024 National Drug Threat Assessment placed carfentanil within a broader pattern of shifting trafficking dynamics, describing its use as either a substitute for or adulterant in fentanyl supplies.
State-level cases put numbers in focus
The national data gains sharper edges at the state level. According to Michigan’s Department of Health and Human Services, 11 deaths involving carfentanil were recorded between January and June 2025, with toxicology showing co-detections of cocaine and fentanyl in those fatalities. The deaths were spread across multiple counties, suggesting the contaminated supply was not confined to a single batch or dealer. As of May 2026, the state has not published a publicly accessible report with those figures online.
In California, the Department of Justice highlighted a 24-pound carfentanil seizure in Fresno during the first half of 2025, which authorities described as the largest single seizure of the substance on record in Northern California. The carfentanil had been pressed into pills designed to look like legitimate prescriptions, a tactic that makes the drug especially lethal for buyers who believe they are purchasing something familiar.
The Alaska case underscored the same danger. Federal prosecutors said the Wasilla defendant sold what he represented as fentanyl on November 14 and 15, 2024. Only after two overdoses, one fatal, did lab analysis reveal the substance was carfentanil.
Why the true scope is hard to measure
For all the confirmed cases, significant gaps remain. SUDORS captures data only from participating jurisdictions, so states without advanced toxicology screening or outside the reporting network may be missing carfentanil-involved deaths entirely. The CDC has acknowledged toxicology testing challenges for carfentanil dating back to a cluster of deaths in Florida in 2016 and 2017, and those limitations persist. Standard postmortem drug panels do not always detect the compound, which means official death counts likely understate the problem.
The drug’s supply chain is also less visible than fentanyl’s. The DEA’s 2024 threat assessment addresses fentanyl analogs broadly and describes shifts in precursor chemical sourcing, but publicly available intelligence does not isolate carfentanil trafficking routes with the same precision. Whether its spread reflects deliberate substitution driven by cost advantages, opportunistic mixing when fentanyl precursors become scarce, or some combination of both has not been established in published research as of spring 2026.
Provisional CDC data shows a broader multiyear decline in total overdose deaths nationally. That trend complicates interpretation. Carfentanil may be spreading within a shrinking overall death toll, or it may be concentrated in specific regions where mortality is rising against the national grain. Until jurisdiction-level breakdowns catch up, the drug’s relative contribution to total overdose figures cannot be reliably quantified.
A drug that punishes small mistakes
What makes carfentanil distinct from fentanyl is not just potency but the margin of error it eliminates. Fentanyl is already dangerous in microgram quantities. Carfentanil compresses that lethality further, meaning even minor inconsistencies in how a batch is mixed can turn a survivable dose into a fatal one. The DEA has described it as a drug “unlike any other” in the current illicit supply.
For emergency responders, that potency raises practical questions. High-potency synthetic opioids can require repeated doses of naloxone to reverse respiratory depression. Field reports during earlier carfentanil outbreaks described prolonged resuscitation efforts that exhausted available naloxone supplies on scene. While naloxone remains effective against carfentanil, agencies may need to ensure larger stockpiles and training that emphasizes multiple-dose protocols when a standard response fails.
Harm reduction organizations are already adjusting. In areas where carfentanil has been detected, some programs have updated outreach materials to stress the unpredictability of pill and powder contents, even for experienced users who believe they are buying a familiar product. Drug checking technologies, including fentanyl test strips and spectrometry-based services, have limits in detecting every analog, but they can flag the presence of unusually potent synthetics and encourage more cautious dosing.
Surveillance gaps that need closing
Public health agencies face a surveillance problem that mirrors the clinical one. Expanding toxicology panels to routinely screen for carfentanil, improving turnaround times for postmortem testing, and integrating law enforcement seizure data with medical examiner reports could all help clarify where the drug is circulating. Without that visibility, local spikes in deaths risk being attributed solely to fentanyl, delaying the targeted warnings that could prompt faster naloxone distribution or safer-use messaging.
The CDC’s Health Alert Network has issued advisories addressing toxic fentanyl-related compounds and counterfeit pill risks, establishing that carfentanil has a documented pattern of cycling through illicit markets. An earlier wave in the mid-2010s was followed by a lull as fentanyl itself dominated the synthetic opioid supply. The current data suggest a renewed phase in which carfentanil is being deployed not as a standalone product but as a hidden ingredient layered into other drugs.
How spring 2026 seizure and mortality data will test the trend
Several concrete developments in the weeks ahead should clarify carfentanil’s trajectory. More detailed CDC releases expected by mid-2026, including jurisdiction-level breakdowns of substances involved in overdose deaths, will indicate whether the drug remains clustered in a handful of states or is diffusing more broadly. If clusters persist, targeted interventions may be feasible. If the spread accelerates, national strategies will need to account for the added risk.
Future DEA reporting will show whether 2024’s seizure volumes were a spike or the beginning of a sustained pattern. Significant increases in kilogram-level seizures, especially combined with counterfeit pills, would suggest entrenched production and distribution networks. A decline could indicate that traffickers are shifting to other analogs or adjusting in response to enforcement pressure.
Policy responses may also shift. Federal and state regulators could revisit scheduling decisions for precursor chemicals, enhance penalties for trafficking ultra-potent opioids, or invest more heavily in forensic laboratory capacity. Public health advocates are likely to press the case that enforcement alone cannot address the underlying drivers of demand and that treatment, housing, and mental health services remain essential.
Carfentanil is not a new drug. Its dangers have been documented for nearly a decade. What has changed is its reappearance in a supply already dominated by fentanyl, at a moment when some measures of overdose risk were finally improving. How quickly surveillance systems adapt, how traffickers respond, and how effectively public health agencies communicate the heightened danger to people who use drugs will determine whether carfentanil becomes a defining feature of the crisis’s next chapter.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
